

<H1>Appendix: Investigators</H1>

<P>In France: Paul Cales, M.D., CHU Angers, Angers; Xavier Causse, M.D., CHR Orléans La Source, Orléans; Francois Habersetzer, M.D., Nouvel Hôpital Civil, Strasbourg; Christian Trepo, M.D., Hôpital Hôtel Dieu, Lyon.</P>

<P>In the United States: Charles Barish, M.D., Wake Research Associates, LLC, Raleigh, NC; Kimberly Beavers, M.D., Asheville Gastroenterology Associates, PA, Asheville, NC; Anuj Bhargava, M.D., Iowa Diabetes & Endocrinology Research Center, Des Moines, IA; Thomas Boyer, M.D., University Medical Center, Tucson, AZ; Charissa Chang, M.D., Mount Sinai Medical Center, New York, NY; Steven Flamm, M.D., Northwestern Memorial Hospital, Chicago, IL; Bradley Freilich, M.D., Kansas City Gastroenterology and Hepatology, Kansas City, MO; Reem Ghalib, M.D., The Liver Institute at Methodist Dallas Medical Center, Dallas, TX; Pierre Gholam, M.D., University Hospital Case Medical Center, Cleveland, OH; John Gilbert, M.D., St. Jude Heritage Medical Group, Fullerton, CA; John Goff, M.D., Rocky Mountain Gastroenterology Associates, Lakewood, CO; Shoba Joshi, M.D., Ochsner Clinic Foundation, New Orleans, LA; Arthur Poch, M.D., Louisiana Research Center, LLC, Shreveport, LA; Paul Pockros, M.D., Scripps Clinic, La Jolla, CA; Nancy Reau, M.D., University of Chicago Hospitals, Chicago, IL; Fredric Regenstein, M.D., Tulane University Health Sciences Center, New Orleans, LA; Shahriar Safavi, M.D., Irving, TX; Thomas Sepe, M.D., University Gastroenterology, Providence, RI; Aasim Sheikh, M.D., Gastrointestinal Specialists of Georgia PC, Marietta, GA; Kirti Shetty, M.D., Georgetown University Hospital, Washington, DC; Roshan Shrestha, M.D., Piedmont Hospital, Atlanta, GA; Ned Snyder III, M.D., University of Texas Medical Branch, Galveston, TX; Hillel Tobias, M.D., Concord Medical Group, New York, NY; Steven Zacks, M.D., Carolina's Medical Center, Charlotte, NC.</P>

Supplementary table.

**Confidence Intervals for Various Standard Deviations and
Expected Difference (U/L) using n = 20 per group**

Common Standard Deviation	Expected Difference (Active – Placebo)	95% Confidence Interval ^a	
		Lower	Upper
25	-20	-36	-4
	-40	-56	-24
	-60	-76	-44
35	-20	-42	2
	-40	-62	-18
	-60	-82	-38
45	-20	-49	9
	-40	-69	-11
	-60	-89	-31

^a confidence intervals are alpha = 0.05, two-sided, based on the t-distribution with 38 degrees of freedom.

A confidence interval table was constructed for various standard deviations and expected active minus placebo differences in ALT (U/L) based on experience with change in ALT in previous studies. For instance based on a worse-case scenario assuming that the common standard deviation is 45 U/L it was calculated that when the sample size in each group is 20, a two-sided 95% confidence interval for the difference of the two mean change from baseline ALT values (active minus placebo) will extend 29 U/L from the observed difference.